Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer

Natera (NTRA) PT Raised to $182 at Jefferies

November 13, 2024 7:35 AM EST

Jefferies analyst Tycho Peterson raised the price target on Natera (NASDAQ: NTRA) to $182.00 (from $142.00) while maintaining a Buy rating.

The analyst comments "NTRA reported another massive beat (+22% vs. Street) driven by strong testing volumes across the board and solid ASPs, while once again... More